Table1_ACNPD: The Database for Elucidating the Relationships Between Natural Products, Compounds, Molecular Mechanisms, and Cancer Types.docx

Objectives: Cancer is well-known as a collection of diseases of uncontrolled proliferation of cells caused by mutated genes which are generated by external or internal factors. As the mechanisms of cancer have been constantly revealed, including cell cycle, proliferation, apoptosis and so on, a series of new emerging anti-cancer drugs acting on each stage have also been developed. It is worth noting that natural products are one of the important sources for the development of anti-cancer drugs. To the best of our knowledge, there is not any database summarizing the relationships between natural products, compounds, molecular mechanisms, and cancer types.Materials and methods: Based upon published literatures and other sources, we have constructed an anti-cancer natural product database (ACNPD) (http://www.acnpd-fu.com/). The database currently contains 521 compounds, which specifically refer to natural compounds derived from traditional Chinese medicine plants (derivatives are not considered herein). And, it includes 1,593 molecular mechanisms/signaling pathways, covering 10 common cancer types, such as breast cancer, lung cancer and cervical cancer.Results: Integrating existing data sources, we have obtained a large amount of information on natural anti-cancer products, including herbal sources, regulatory targets and signaling pathways. ACNPD is a valuable online resource that illustrates the complex pharmacological relationship between natural products and human cancers.Conclusion: In summary, ACNPD is crucial for better understanding of the relationships between traditional Chinese medicine (TCM) and cancer, which is not only conducive to expand the influence of TCM, but help to find more new anti-cancer drugs in the future.</p

Manipulating the Electrocatalytic Performance of NiCoP Nanowires by V Doping Under Acidic and Basic Conditions for Hydrogen and Oxygen Evolution Reactions

It is critical to design bifunctional nonprecious electrocatalysts with low costs and high efficiency for hydrogen production. Conventional electrocatalysts, on the other hand, frequently exhibit significant overpotential and slow transfer kinetics in both hydrogen and oxygen evolution reactions (HER and OER). Cation doping engineering is believed to be a suitable way to deal with this problem. To accomplish effective water electrolysis, we use a simple vanadium ion doping strategy to prepare 0.5V-NiCoP. In acidic and alkaline environments, the as-synthesized samples show an overpotential of 78.7 and 56.1 mV for the HER at 10 mA cm–2, respectively. In 1 M KOH, it shows an overpotential of 254 mV for the OER at 50 mA cm–2. Furthermore, under a two-electrode alkaline state, the as-obtained products only require 1.67 V (50 mA cm–2) to drive water splitting

sj-pdf-2-imr-10.1177_03000605211065942 - Supplemental material for Retrospective study of active drainage in the management of anastomotic leakage after anterior resection for rectal cancer

Supplemental material, sj-pdf-2-imr-10.1177_03000605211065942 for Retrospective study of active drainage in the management of anastomotic leakage after anterior resection for rectal cancer by Xiaojie Tan, Mei Zhang, Lai Li, He Wang, Xiaodong Liu and Haitao Jiang in Journal of International Medical Research</p

sj-pdf-1-imr-10.1177_03000605211065942 - Supplemental material for Retrospective study of active drainage in the management of anastomotic leakage after anterior resection for rectal cancer

Supplemental material, sj-pdf-1-imr-10.1177_03000605211065942 for Retrospective study of active drainage in the management of anastomotic leakage after anterior resection for rectal cancer by Xiaojie Tan, Mei Zhang, Lai Li, He Wang, Xiaodong Liu and Haitao Jiang in Journal of International Medical Research</p

Subgroup analysis results of overall survival in advanced NSCLC patients according to <i>BRCA1</i> rs1799966 genotypes (TT <i>vs.</i> TC+CC).

<p>(A) Squamous cell carcinoma group, (B) ever smokers group, (C) ECOG performance status  = 1 group, (D) stage III group. Number in parenthesis, number of deaths/number of cases.</p

Associations of Polymorphisms in DNA Repair Genes and MDR1 Gene with Chemotherapy Response and Survival of Non-Small Cell Lung Cancer

<div><p>Objectives</p><p>We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (<i>ERCC1</i>) rs11615, xeroderma pigmentosum group D (<i>XPD</i>/<i>ERCC2)</i> rs13181, X-ray repair cross complementing group 1 (<i>XRCC1</i>) rs25487, <i>XRCC3</i> rs1799794, and breast cancer susceptibility gene 1 (<i>BRCA1</i>) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (<i>MDR1/ABCB1</i>) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.</p><p>Materials and Methods</p><p>A total of 352 NSCLC patients were enrolled to evaluate the associations of the six SNPs with response to chemotherapy and overall survival. Logistic regressions were applied to test the associations of genetic polymorphisms with response to chemotherapy in 161 advanced NSCLC patients. Overall survival was analyzed in 161 advanced and 156 early stage NSCLC patients using the Kaplan-Meier method with log-rank test, respectively. Multivariate Cox proportional hazards model was performed to determine the factors independently associated with NSCLC prognosis.</p><p>Results</p><p><i>BRCA1</i> rs1799966 minor allele C (TC+CC <i>vs.</i> TT, OR = 0.402, 95%CI = 0.204−0.794, p = 0.008) and <i>MDR1/ABCB1</i> rs1045642 minor allele A (GA +AA <i>vs.</i> GG, OR = 0.478, 95%CI = 0.244−0.934, p = 0.030) were associated with a better response to chemotherapy in advanced NSCLC patients. Survival analyses indicated that <i>BRCA1</i> rs1799966 TC+CC genotypes were associated with a decreased risk of death (HR = 0.617, 95% CI = 0.402−0.948, p = 0.028) in advanced NSCLC patients, and the association was still significant after the adjustment for covariates. Multivariate Cox regression analysis showed that <i>ERCC1</i> rs11615 AA genotype (<i>P</i> = 0.020) and smoking (p = 0.037) were associated with increased risks of death in early stage NSCLC patients after surgery.</p><p>Conclusions</p><p>Polymorphisms of genes in DNA repair pathway and <i>MDR1</i> could contribute to chemotherapy response and survival of patients with NSCLC.</p></div

Subgroup analysis results of overall survival in early stage NSCLC patients according to <i>ERCC1</i> genotypes (GG+GA vs. AA).

<p>(A) Squamous cell carcinoma group, (B) ever smokers group, (C) ECOG performance status  = 1 group, (D) never receiving radiation therapy group. Number in parenthesis, number of deaths/number of cases.</p

Demographic and clinical characteristics of the NSCLC patients.

<p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, stand deviation.</p><p>*<i>P</i> values refer to the comparison between early stage patients with surgery and advanced patients with chemotherapy. Student's t-test was used to compare age as a continuous variable; chi-square test was used to compare categorical variables, except for ECOG performance status, where Fisher's exact test was used.</p>†<p>Comparisons between never smokers and ever smokers.</p

Associations of genotype and clinical stage with clinical benefit of chemotherapy among advanced NSCLC patients (N = 161).

<p>Abbreviations: CR, complete response; OR, odds ratio; PD, progressive disease; PR, partial response; SD, stable disease.</p><p>*Adjusted for <i>BRCA1</i> rs1799966, <i>MDR1/ABCB1</i> rs1045642 and clinical stage, adjusted ORs and P values were obtained from multivariate logistic regression analysis by forward stepwise method.</p

Factors associated with overall survival of early stage NSCLC patients.

<p>(A) <i>ERCC1</i> rs11615, (B) smoking status.</p